^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serotonin reuptake inhibitor

    Related drugs:
    1d
    Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy. (PubMed, J Pharm Pharmacol)
    Sex is a crucial biological variable in CIPN, influencing drug efficacy through sex-specific neuroimmune mechanisms and hormonal regulation. These findings underscore the necessity of incorporating sex as a key variable in analgesic development and clinical practice to achieve personalized pain management in CIPN patients.
    Review • Journal
    |
    TLR9 (Toll Like Receptor 9) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    2d
    A Randomized, open label, Non-inferiority trial on the efficacy of Lacosamide versus Duloxetine in Patients with Chemotherapy-induced Polyneuropathy - A strategy trial (2024-511008-17-00)
    P4, N=110, Completed, Leids Universitair Medisch Centrum (LUMC) | Not yet recruiting --> Completed
    Trial completion • Head-to-Head
    3d
    Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy (clinicaltrials.gov)
    P4, N=93, Recruiting, Iuliu Hatieganu University of Medicine and Pharmacy | Not yet recruiting --> Recruiting
    Enrollment open
    3d
    NEFOPAIN kinet: Pharmacokinetic Study of the Use of Nefopam 30 mg Tablets in Patients Suffering From Acute Pain in Rheumatology (clinicaltrials.gov)
    P4, N=24, Not yet recruiting, University Hospital, Rouen
    New P4 trial
    4d
    Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects (clinicaltrials.gov)
    P1, N=44, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P1 trial
    9d
    CHDR2501: Research into new test methods to measure pain with two existing drugs (nefopam and oxycodone) (2025-522389-66-00)
    P1, N=24, Completed, Centre for Human Drug Research | Recruiting --> Completed
    Trial completion
    9d
    Duloxetine for Perioperative Pain in Hip Arthroplasty: A RCT (clinicaltrials.gov)
    P4, N=64, Recruiting, University of Miami | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    10d
    Study to compare the effectiveness of Venlafaxine to Placebo in treating MDD or PDD in children. (clinicaltrialsregister.eu)
    P3, N=160, Viatris Pharmaceutical Japan GK
    New P3 trial
    10d
    Study to evaluate safety and efficacy of Venlafaxine in treating MDD or PDD in children who completed VENL-CAZ-3001 study (clinicaltrialsregister.eu)
    P3, N=145, Viatris Pharmaceutical Japan GK
    New P3 trial
    15d
    Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder (clinicaltrials.gov)
    P1, N=52, Completed, Intra-Cellular Therapies, Inc. | Recruiting --> Completed | Trial completion date: Mar 2026 --> Nov 2025
    Trial completion • Trial completion date
    15d
    A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine (clinicaltrials.gov)
    P1, N=62, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P1 trial
    15d
    SNRI: Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures (clinicaltrials.gov)
    P4, N=100, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Dec 2026 --> Dec 2028 | Trial completion date: Dec 2026 --> Dec 2028
    Trial completion date • Trial primary completion date